CE-Ventures, the corporate venture capital arm of UAE-based Crescent Enterprises, has announced its participation in a $10 million financing round for CrossBridge Bio, a Houston-based biotech firm pioneering dual-payload antibody-drug conjugates (ADCs) for targeted cancer therapies. The round, co-led with TMC Venture Fund, will support CrossBridge Bio’s efforts to advance its lead candidate, CBB-120, as a potential treatment for solid tumors and further expand its dual-payload ADC pipeline. Additionally, the funds will bolster the development of its proprietary linker technology, a crucial component for enhancing the safety and effectiveness of its therapeutic platform.

“Crescent Enterprises is dedicated to further expanding our life science portfolio with cutting-edge biotech companies,” said Tushar Singhvi, Deputy CEO and Head of Investments at Crescent Enterprises. “CrossBridge Bio exemplifies the innovation in therapeutic drug development that we are committed to supporting more in the future.”

Damir Illich, PhD, Manager Life Sciences at CE-Ventures and newly appointed board director of CrossBridge Bio, added: “CrossBridge Bio is a new leader in the dual-payload ADC drug discovery and development arena. We are proud to support their efforts to advance the lead candidate CBB-120 through preclinical studies and to expand the pipeline of dual-payload ADC programs.”

“We are proud to have the support of such experienced investors who share our vision of transforming cancer therapy,” said Michael Torres, PhD, CEO of CrossBridge Bio. “Our dual-payload ADC technology is designed to maximize therapeutic effectiveness by delivering targeted therapies directly into cancer cells, minimizing potential off-target effects. With this support, we plan to advance CBB-120 into preclinical non-GLP toxicology studies to enable its future clinical development.”

CE-Ventures, which has deployed over $500 million globally across more than 50 investments, focuses on high-growth companies in technology and life sciences, with a focus on novel therapeutics and microbiome-based therapies. Other participants in CrossBridge Bio’s financing round include TMC Venture Fund, Portal Innovations, Alexandria Ventures, and several pre-seed investors.

About Crescent Enterprises

Crescent Enterprises is a leading multinational company, growing diversified global businesses that are sustainable, scalable, and profitable.  Headquartered in the United Arab Emirates, with business operations in 15 countries, it operates under four enterprise platforms:

  • CE-Operates, an operating business platform, focusing on smart infrastructure as the main driver of economic development and growth.
  • CE-Invests, a strategic investment platform investing in late-stage businesses and private equity funds.
  • CE-Ventures, a corporate venture capital platform targeting early-stage technology-enabled high-growth businesses and venture capital funds globally.
  • CE-Creates, an internal business incubator, building start-ups that are socially and environmentally conscious.

Crescent Enterprises operates with a value system and culture that embraces corporate governance, inclusive growth, and responsible business practices.

For further information, please visit:
www.crescententerprises.com
Crescent Enterprises
CrescentEnterp